Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging

被引:8
|
作者
Monkman, James [1 ]
Moradi, Afshin [1 ]
Yunis, Joseph [1 ,2 ]
Ivison, Geoff [3 ]
Mayer, Aaron [3 ]
Ladwa, Rahul [4 ]
O'Byrne, Ken [4 ]
Kulasinghe, Arutha [1 ]
机构
[1] Univ Queensland, Frazer Inst, Fac Med, 37 Kent St, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Fac Med, Ian Frazer Ctr Childrens Immunotherapy Res, Childrens Hlth Res Ctr, Brisbane, Qld, Australia
[3] Enable Med, Menlo Pk, CA USA
[4] Princess Alexandra Hosp, Brisbane, Qld, Australia
关键词
IMMUNITY;
D O I
10.1186/s12967-024-05035-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The spatial localisation of immune cells within tumours are key to understand the intercellular communications that can dictate clinical outcomes. Here, we demonstrate an analysis pipeline for highly multiplexed CODEX data to phenotype and profile spatial features and interactions in NSCLC patients that subsequently received PD1 axis immunotherapy. We found that regulatory T cells (Tregs) are enriched in non-responding patients and this was consistent with their localization within stromal and peripheral tumour-margins. Proximity-based interactions between Tregs and both monocytes (p = 0.009) and CD8+ T cells (p = 0.009) were more frequently found in non-responding patients, while macrophages were more frequently located in proximity to HLADR+ tumour cells (p = 0.01) within responding patients. Cellular neighbourhoods analysis indicated that both macrophages (p = 0.003) and effector CD4+ T cells (p = 0.01) in mixed tumour neighbourhoods, as well as CD8+ T cells (p = 0.03) in HLADR+ tumour neighbourhoods were associated with favorable clinical response. Evaluation of the inferred regulatory functions between immune cells relative to the tumour suggested that macrophages exhibit an immunosuppressive phenotype against both CD4+ and CD8+ T cells, and that this association scores more highly in ICI refractory patients. These spatial patterns are associated with overall survival in addition to ICI response and may thus indicate features for the functional understanding of the tumour microenvironment.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC)
    Li, Rui
    Lee, Gina
    El-Sherief, Ahmed
    BMJ CASE REPORTS, 2019, 12 (03)
  • [12] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [13] Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
    Chiu, Li-Chung
    Lin, Shu-Min
    Lo, Yu-Lun
    Kuo, Scott Chih-Hsi
    Yang, Cheng-Ta
    Hsu, Ping-Chih
    VACCINES, 2021, 9 (07)
  • [14] Immuntherapie des nichtkleinzelligen Lungenkarzinoms (NSCLC)Immunotherapy for non-small cell lung cancer (NSCLC)
    Nikolaj Frost
    Martin Reck
    Die Innere Medizin, 2022, 63 (7) : 709 - 716
  • [15] The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
    Brahmer, Julie R.
    Govindan, Ramaswamy
    Anders, Robert A.
    Antonia, Scott J.
    Sagorsky, Sarah
    Davies, Marianne J.
    Dubinett, Steven M.
    Ferris, Andrea
    Gandhi, Leena
    Garon, Edward B.
    Hellmann, Matthew D.
    Hirsch, Fred R.
    Malik, Shakuntala
    Neal, Joel W.
    Papadimitrakopoulou, Vassiliki A.
    Rimm, David L.
    Schwartz, Lawrence H.
    Sepesi, Boris
    Yeap, Beow Yong
    Rizvi, Naiyer A.
    Herbst, Roy S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [16] The influence of circulating tumor DNA analysis on response to immunotherapy in non-small cell lung cancer (NSCLC)
    Grinberg, R.
    Roisman, L. C.
    Geva, S.
    Soussan-Gutman, L.
    Dvir, A.
    Yair, R.
    Twito, T.
    Larman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S35 - S36
  • [17] Identifying predictive biomarkers for long term response on immunotherapy in non-small cell lung cancer (NSCLC)
    Decoster, L.
    Nazari, S.
    De Ridder, K.
    Giron, P.
    Vekens, K.
    Goyvaerts, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1052 - S1052
  • [18] The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Grinberg, R.
    Roisman, L.
    Geva, S.
    Lefterova, M.
    Quinn, K.
    Gutman, L. Soussan
    Dvir, A.
    Yair, R.
    Twito, T.
    Lanman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S925 - S926
  • [19] Multi-omic dissection of immunotherapy response groups in non-small cell lung cancer (NSCLC)
    Kulasinghe, Arutha
    Monkman, James
    Kim, Honesty
    Mayer, Aaron
    Mehdi, Ahmed
    Matigian, Nicholas
    Cumberbatch, Marie
    Bhagat, Milan
    Ladwa, Rahul
    Mueller, Scott
    Adams, Mark
    O'Byrne, Ken
    CANCER RESEARCH, 2022, 82 (12)
  • [20] Immunotherapy for Non-Small Cell Lung Cancer
    Yoon, Sung Ho
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 77 (03) : 111 - 115